Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.

The objective of this study was to assess the prognostic relevance of preoperative serum anti-p53 antibodies in epithelial ovarian cancer. These autoantibodies were detected with a new generation enzyme-linked immunosorbent assay in blood samples preoperatively drawn from 86 patients with this malignancy. Serum anti-p53 antibodies were found in 3 (10.0%) of the 30 patients with stage I-II and 15 (26.8%) of the 56 patients with stage III-IV epithelial ovarian cancer (P = 0.09). We assessed in detail 44 patients with stage III-IV disease who underwent six cycles of first-line platinum-based chemotherapy. A pathological complete response at second-look was achieved by none of the 15 patients with serum anti-p53 antibodies compared to 24.1% of the 29 patients without autoantibodies (P = 0.09). However, the preoperative serum anti-p53 antibody status had no prognostic relevance for progression-free survival and survival. In conclusion, the assessment of preoperative serum anti-p53 antibodies seems to have a limited clinical value in the management of patients with advanced epithelial ovarian cancer.

[1]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[2]  S. H. van der Burg,et al.  Antibodies against p53 are associated with poor prognosis of colorectal cancer. , 1995, British Journal of Cancer.

[3]  G. Viale,et al.  p53 accumulation in ovarian carcinomas and its prognostic implications. , 1993, Human pathology.

[4]  T. Soussi,et al.  Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. , 1994, British Journal of Cancer.

[5]  J. Marks,et al.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Warwick,et al.  The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. , 1996, Cancer research.

[7]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[8]  D. Lane,et al.  The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. , 1992, Cancer research.

[9]  J. Bonneterre,et al.  Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer , 1995, The Lancet.

[10]  A. Marchetti,et al.  p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. , 1993, Cancer research.

[11]  Leland Hartwell,et al.  Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.

[12]  S. Syrjänen,et al.  Implications of the p53 tumor-suppressor gene in clinical oncology. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[14]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[15]  J. Minna,et al.  Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. , 1992, Cancer research.

[16]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[17]  A. Eastman,et al.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. , 1990, Biochemical pharmacology.

[18]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[19]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[20]  S. Leinster,et al.  The relationship between serum p53 autoantibodies and characteristics of human breast cancer. , 1994, British Journal of Cancer.

[21]  D. Lane.  A death in the life of p53 , 1993, Nature.

[22]  E. Diamandis,et al.  Circulating antibodies against p53 protein in patients with ovarian carcinoma , 1996, Cancer.

[23]  Anne Fajao,et al.  Cisplatin‐induced apoptosis and p53 gene status in a cisplatin‐resistant human ovarian carcinoma cell line , 1996, International journal of cancer.

[24]  A. Gadducci,et al.  Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. , 1995, Gynecologic oncology.

[25]  P. Laurent-Puig,et al.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. , 1993, Cancer research.

[26]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[27]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[28]  J. Green,et al.  Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. , 1995, Cancer detection and prevention.

[29]  T. Soussi,et al.  Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.

[30]  E. Diamandis,et al.  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers , 1994, International journal of cancer.

[31]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[32]  S. Ménard,et al.  A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. , 1996, Cancer research.

[33]  R. Lubin,et al.  Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. , 1994, Leukemia.

[34]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[35]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[36]  D. Thomson,et al.  Analysis of the anti-p53 antibody response in cancer patients. , 1993, Cancer research.

[37]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[38]  J. Minna,et al.  Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. , 1993, Journal of the National Cancer Institute.

[39]  P. Humphrey,et al.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. , 1993, Obstetrics and gynecology.

[40]  T. Soussi,et al.  p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue , 1995, International journal of cancer.

[41]  F. Buttitta,et al.  Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. , 1996, Anticancer Research.

[42]  A. Marchetti,et al.  p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. , 1997, British Journal of Cancer.

[43]  P. Sismondi,et al.  Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma , 1995, Cancer.